TIGIT+ iTregs elicited by human regulatory macrophages control T cell immunity by Riquelme, Paloma et al.
ARTICLE
TIGIT+ iTregs elicited by human regulatory
macrophages control T cell immunity
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Human regulatory macrophages (Mreg) have shown early clinical promise as a cell-based
adjunct immunosuppressive therapy in solid organ transplantation. It is hypothesised that
recipient CD4+ T cell responses are actively regulated through direct allorecognition of
donor-derived Mregs. Here we show that human Mregs convert allogeneic CD4+ T cells to
IL-10-producing, TIGIT+ FoxP3+-induced regulatory T cells that non-speciﬁcally suppress
bystander T cells and inhibit dendritic cell maturation. Differentiation of Mreg-induced Tregs
relies on multiple non-redundant mechanisms that are not exclusive to interaction of Mregs
and T cells, including signals mediated by indoleamine 2,3-dioxygenase, TGF-β, retinoic acid,
Notch and progestagen-associated endometrial protein. Preoperative administration of
donor-derived Mregs to living-donor kidney transplant recipients results in an acute increase
in circulating TIGIT+ Tregs. These results suggest a feed-forward mechanism by which Mreg
treatment promotes allograft acceptance through rapid induction of direct-pathway Tregs.
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Adoptive transfer of immunoregulatory cells as a means ofestablishing transplantation tolerance is a commonexperimental technique, but its clinical application is only
now receiving serious attention1. Several classes of immunor-
egulatory cells are currently being developed as adjunct immu-
nosuppressive agents for use in solid organ transplantation,
including different sorts of regulatory T cells (Treg)2 and sup-
pressive myeloid cells3. The human regulatory macrophage
(Mreg) is a promising candidate cell type that is already far
advanced in its development as a cell-based medicinal product4.
Mregs are currently being investigated in the ONEmreg12 trial, a
phase-I/II study of Mreg therapy as a means of safely minimising
maintenance immunosuppression in kidney transplant recipients
(clinicaltrials.gov: NCT02085629).
Human Mregs reﬂect a unique state of macrophage differ-
entiation, distinguished from macrophages in other activation
states by their mode of derivation, cell-surface phenotype, stable
DHRS9 expression5 and potent suppressor function. Human
Mregs develop from macrophage colony-stimulating factor (M-
CSF; CSF1)-stimulated CD14+ peripheral blood monocytes6
cultured with high concentrations of human serum7 through a
time-dependent process8 that requires contact with a plastic
surface, ligation of FcγRIII (CD16) by serum immunoglobulin9
and exposure to other serum factors. Human Mregs prevent
mitogen-stimulated allogeneic T cell proliferation in vitro
through interferon (IFN)-γ-induced indoleamine 2,3-dioxygenase
(IDO) activity, as well as mediating a contact-dependent deletion
of activated allogeneic T cells10. From a technological perspective,
the simplicity of Mreg production and their stable suppressive
activity are qualities that lend themselves well to a cell-based
therapeutic product for use as an immunosuppressive, anti-
inﬂammatory or tissue-reparative therapy11.
Preclinical experiments in a heterotopic mouse heart transplant
model demonstrated that intravenous (i.v.) injection of donor-
strain Mregs conferred long-term transplant acceptance to non-
immunosuppressed, fully allogeneic recipients12. Importantly,
this allograft-protective effect was not simply due to alloantigen
exposure but depended upon Mregs expressing inducible nitric
oxide synthase. Following i.v. injection into mice, allogeneic
Mregs rapidly accumulated in lung, liver and spleen, but not in
lymph nodes, where a proportion of transferred Mregs persisted
for up to 4 weeks. Importantly, these experiments showed that
living Mregs exerted a graft-protective effect that endured beyond
their lifespan, which was likely mediated by recipient T cells.
Although mouse and human Mregs suppress allogeneic T cell
proliferation and effector functions in vitro, it remains con-
troversial whether they can control recipient alloimmune
responses in vivo through direct interaction of transferred cells
with recipient T cells.
Here we explore the possibility that adoptive transfer of donor-
derived Mregs to an allogeneic recipient prior to solid organ
transplantation induces recipient Tregs through direct interac-
tions between donor and recipient cells. It is hypothesised that
transient Mreg-induced Treg responses might engender more
stable regulatory responses through a feed-forward mechanism
sustained by recipient antigen-presenting cells and Tregs. This
study investigates phenotypic and functional changes wrought by
human Mregs upon allogeneic CD4+ T cells in coculture in order
to identify markers that might allow us to infer direct interactions
between donor-derived Mregs and recipient T cells in Mreg-
treated patients. In coculture and humanised mouse experiments,
a fraction of CD4+ T cells converts to interleukin (IL)-10-
expressing-induced Tregs (iTregs) through an activation-
dependent process reliant upon CD28, IDO, retinoic acid,
transforming growth factor-β (TGF-β), canonical Notch signal-
ling and progestagen-associated endometrial protein (PAEP).
After i.v. administration of donor-derived Mregs, increased
TIGIT+ Treg frequencies are observed in the peripheral blood of
prospective kidney transplant recipients. Taken together, these
ﬁndings suggest TIGIT+ iTreg elicited by allogeneic Mreg therapy
could play a mechanistically important role in its tolerogenic
effects.
Results
Steady-state characteristics of human Mregs. Human Mregs
arose from puriﬁed CD14+ peripheral blood monocytes cultured
in medium supplemented with human AB serum and M-CSF
(CSF1) for 6 days prior to stimulation with IFN-γ for 18–24 h.
Mregs adopted a distinctive tessellating, epithelioid morphology
to form almost conﬂuent monolayers (Fig. 1a). Individual cells
were large and densely granular with a prominent central body
and thin cytoplasmic skirt that spread symmetrically over the
surface of the culture vessel. Ultrastructural examination con-
ﬁrmed the impression of ﬂattened cells adhering very closely to
the underlying plastic surface (Fig. 1b). Membranous processes
extended from the perimeter and upper surface of Mregs, and
their nuclei appeared active with abundant ﬁne chromatin—fea-
tures typical of activated human macrophages. Over a 9-h time
course, Mregs exhibited a higher rate and absolute capacity for
phagocytosis of ﬁxed, ﬂuorescently labelled Escherichia coli than
classically (IFN-γ+ lipopolysaccharide; LPS) activated macro-
phages (Fig. 1c).
Human Mregs expressed generic markers of human macro-
phages, including CD11b, CD33 and human leukocyte antigen
(HLA)-DR (Fig. 1d). Unlike other monocyte-derived macro-
phages, Mregs expressed relatively low levels of CD14 and cell-
surface CD16. Similar to CD14low non-classical monocytes,
Mregs expressed CX3CR1. Mregs uniformly expressed CD11c
and XCR1, but they lacked CLEC9a and CD141 expression, so
Mregs are not cDC1-like cells. Mregs expressed CD172a (SIRPα)
but not CD1a or CD1c; therefore, Mregs are not cDC2-like cells.
In common with pDC, human Mregs expressed CD123 (IL-3R)
and CD304 (NRP1). Mregs expressed typical markers of tissue-
resident macrophage subsets, including CD64, CD163, CD169,
CD204 (MSR), CD206 (MMR), CD209, CD301 (MGL1), LYVE-
1, Factor XIIIa and MER. A variety of inhibitory receptors were
expressed by Mregs, including members of the LILR (ILT) family
and TREM2. Intracellular staining for IDO revealed homoge-
neous expression by Mregs. A survey of extra- and intracellular
expression of costimulatory and co-inhibitory ligands revealed
human Mregs were CD80−/low CD86+ CD273+ CD274+
CD275− CD279+ CD270+ CD112+ CD155+ Galectin-9+
CD48+ CD252+ CD70− GITRL+ CD153+ CD258+ CD160−
CD178− CD40+ CD253− (Supplementary Figure 1). Given their
mode of derivation, morphology and cell-surface phenotype,
human Mregs are best classiﬁed as a subset of monocyte-derived
macrophages13.
Mreg-mediated enrichment of IL-10-producing FoxP3+ T cells.
The consequences of exposing CD3+ T cells to allogeneic Mregs
in vitro were investigated in coculture experiments (Fig. 2a). To
gauge their capacity for bystander suppression, Mreg-cocultured
T cells were re-isolated and mixed with autologous carboxy-
ﬂuorescein succinimidyl ester (CFSE)-labelled responder T cells
(Fig. 2b). At suppressor:responder ratios of >1:5, responder T cell
proliferation stimulated with plate-bound anti-CD3 was inhibited
by Mreg-cocultured T cells, whereas T cells cultured in the
absence of Mregs were not suppressive. To test whether Mreg-
cocultured T cells inhibited monocyte-derived dendritic cell (mo-
DC) maturation, Mreg-cocultured allogeneic CD4+ T cells were
ﬂow-sorted and added at a 2:1 ratio to immature mo-DCs. These
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mo-DCs were then stimulated with tumour necrosis factor alpha
(TNFα) over 2 days before assessing their maturation state. Mreg-
cocultured T cells partially inhibited the upregulation of CD80
and CD83 (Fig. 2c). Mreg-cocultured allogeneic CD4+ T cells
were enriched for a CD25+FoxP3+ subset (Fig. 2d and
Supplementary Figure 2). An equivalent population did not
emerge from T cell cultures after stimulation with plate-bound
anti-CD3 for 5 days in the absence of Mregs. Twenty-four-hour
secretion of IL-10 by anti-CD3-stimulated CD4+ T cells re-
isolated from allogeneic Mreg cocultures was signiﬁcantly greater
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Fig. 1 Steady-state characteristics of human Mregs. a Plastic-adherent Mregs acquired a distinctive morphology (bar= 50 μm). b Transmission electron
micrographs of Mregs revealed typical morphological features of activated human macrophages (bar= 2 μm). c Phagocytic uptake of ﬂuorescently
labelled, ﬁxed E. coli by human Mregs and classically (IFN-γ+ LPS) activated macrophages over a 9-h time course (mean ± sd; n= 3). d Phenotyping of
human Mregs by ﬂow cytometry conﬁrmed that Mregs are monocyte-derived macrophages: red= speciﬁc signal; grey= isotype control (representative of
n= 6)
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Fig. 2 Mreg-cocultured T cells inhibit T-cell proliferation and mo-DC maturation. The functional consequences of exposing CD3+ T cells to allogeneic
Mregs were investigated in coculture experiments. a Human Mregs generated from CD14+ monocytes were cultured together with allogeneic T cells for
5 days. T cells were then analysed by ﬂow cytometry, qPCR, microarray and functional assays. b Proliferation of CFSE-labelled responder CD4+ T cells
stimulated with plate-bound αCD3 was inhibited by allogeneic Mreg-cocultured T cells to a greater degree than by T cells cultured alone for 5 days (n= 6;
mean ± sd). c CD4+ T cells ﬂow-sorted from Mreg cocultures antagonised upregulation of CD80 and CD83 by mo-DCs stimulated with 50 ngml−1 TNFα
for 2 days (representative of n= 6). d CD3+ T cells cocultured with allogeneic Mregs for 5 days were enriched for FoxP3+ T cells that were readily
discriminated from CD25+ FoxP3−/low T cells activated by αCD3/αCD28 stimulation for 5 days (representative of n= 4). e Twenty-four-hour secretion of
IL-10 by αCD3-stimulated CD4+ T cells re-isolated from allogeneic Mreg cocultures (n= 4; KW). f Most IL-10-producing T cells from Mreg cocultures
were FoxP3+ T cells and vice versa (representative of n= 6 donors). g Enrichment of FoxP3+ T cells from naive CD25− CD45RA+ CD4+ T cells, which
were predominantly FoxP3−, was signiﬁcantly more efﬁcient than enrichment from unfractionated CD3+ T cells (n= 6; MW). h Coculture with allogeneic
Mregs led to a signiﬁcant enrichment of FoxP3+ T cells from a starting population of unfractionated CD3+ T cells. By contrast, CD3+ T cells that were
unstimulated, polyclonally activated or cocultured with IFN-γ Mφ were not enriched for FoxP3+ T cells (n= 6; KW). i No increase in TSDR demethylation
was observed in CD3+ T cells cocultured with Mregs; therefore, enrichment of FoxP3+ T cells reﬂects conversion of non-Tregs (n= 6; KW)
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than IL-10 production under control conditions (Fig. 2e). FoxP3+
Tregs were primarily responsible for this IL-10 secretion (Fig. 2f).
Together, these ﬁndings show that Mregs enriched cocultured
T cells for IL-10-producing FoxP3+ Tregs. This experimental
system serves as the basis for subsequent in vitro experiments.
The emergence of FoxP3+ T cells after Mreg coculture could be
explained by proliferation or passive enrichment of FoxP3+ Tregs
present at the start of coculture, or by conversion from FoxP3−
T cells. To distinguish between these possibilities, Mregs were
cocultured with either unfractionated CD3+ T cells or negatively
isolated naive CD4+ T cells, which typically contained fewer than
2.1 ± 0.9% FoxP3+ T cells. Despite naive T cell preparations
containing fewer FoxP3+ Tregs prior to Mreg coculture,
generation of FoxP3+ T cells from naive allogeneic CD4+ T cells
was signiﬁcantly more effective than from unfractionated T cells
(Fig. 2g). Enrichment of FoxP3+ T cells within 5 days was
observed when T cells were cocultured with Mregs, but not
following coculture with control IFN-γ-stimulated macrophages
(IFN-γ Mφ) from the same monocyte donors (Fig. 2h and
Supplementary Figure 3). No enrichment of FoxP3+ T cells was
observed when T cells were cultured in the absence of Mregs,
either with or without polyclonal stimulation using anti-CD3/
CD28 beads. Hence, enrichment of FoxP3+ T cells appeared to be
a specialised function of Mregs, as opposed to a general
consequence of T cell activation. Helios was expressed by a
minority (5.0 ± 0.68%; n= 6) of FoxP3+ T cells suggesting that
Mreg-enriched FoxP3+ T cells do not principally derive from
nTregs. Consistent with this interpretation, Treg-speciﬁc
demethylated region (TSDR) demethylation in Mreg-cocultured
T cells was only 1.35 ± 1.03% (Fig. 2i). Therefore, Mreg coculture
leads to induction of FoxP3 expression in previously FoxP3–
CD4+ T cells.
To assess the allospeciﬁcity of Mreg-cocultured T cell-mediated
T cell-suppression, the following experiment was performed
(Fig. 3a). Paired cultures of Mregs and mo-DCs were generated
over 7 days from three unrelated donors: Mregs were then
cocultured with allogeneic CD3+ T cells from a further two
unrelated donors for 3 days leading to an enrichment of FoxP3+
T cells (25.9 ± 4.2%, n= 6 pairs). In parallel, mo-DCs were
matured with TNFα. Subsequently, the capacity of CD3+ T cells
re-isolated from Mreg cocultures to suppress allogeneic DC-
driven proliferation of responder T cells (which were autologous
to Mreg-cocultured T cells) was tested. Explicitly, re-isolated
CD3+ T cells (not puriﬁed FoxP3+ T cells) were used as the
suppressor population in these experiments; therefore, Mreg-
induced FoxP3+ T cells represented only 8.1 ± 1.5% of all T cells
initially present. Mreg-cocultured T cells suppressed both CD4+
and CD8+ responder T cells equally strongly when stimulator
DCs were autologous or allogeneic to Mregs used in the initial
coculture phase (Fig. 3b). That is to say, Mreg-cocultured T cells
did not behave as allospeciﬁc suppressors in this experimental
system. Nevertheless, it should be noted that FoxP3+ CD4+
T cells from Mreg cocultures are already activated and secrete IL-
10 without further stimulation. Accordingly, these results show
that freshly re-isolated Mreg-cocultured T cells mediate short-
term, non-speciﬁc ‘bystander’ suppression, but they do not prove
that initial activation of naive CD4+ T cells by Mregs is not
allospeciﬁc or that Mreg-induced FoxP3+ CD4+ T cells would
not suppress in an allo-restricted fashion in vivo.
Phenotype of Mreg-cocultured CD4+ CD25+ FoxP3+ T cells. It
is well-established that activation of conventional human CD4+
T cells induces transient expression of FoxP3 and other Treg
markers; moreover, such activated effector cells can suppress
proliferation of responder T cells in vitro through competitive or
cytotoxic mechanisms that may not reﬂect their true regulatory
activity. Therefore, we ﬁrst sought to discriminate Mreg-induced
FoxP3+ T cells from activated effector T cell subsets. An extensive
survey was made of markers expressed by FoxP3+ and FoxP3−
CD25+ T cells from Mreg cocultures (Fig. 4a and Supplementary
Figure 4A). FoxP3+ CD25+ T cells expressed higher levels of
CD39, CD137 (4-1BB), intracellular CD152 (CTLA4), CD357
(GITR) and GARP than their FoxP3− counterparts (Fig. 4a, b).
Conversely, FoxP3− CD25+ T cells expressed higher levels of
CD6, CD127 (IL7RA) and KLRG1 than FoxP3+ T cells. Following
Mreg exposure, FoxP3+ T cells expressed markers of T cell acti-
vation, which led us to ask whether they represented a subset of
exhausted T cells or a type of differentiated memory T cell.
Exhaustion and senescence of CD4+ T cells is associated with a
CD27low CD28low CD57+ KLRG1+ CD223+ CD279+ phenotype;
however, Mreg-enriched FoxP3+ T cells were CD27high CD28high
CD57− KLRG1−/low CD223−/low and CD279+ (Fig. 4a) so do not
appear to be exhausted or senescent T cells. Human CD4+ TEMRA
cells are typically described as CD27low CD28low CD45RA+
CD62L− CD122+ T cells; therefore, CD27high CD28high
CD45RA+/− CD62L+ CD122−Mreg-enriched FoxP3+ T cells are
not CD4+ TEMRA (Fig. 4a and Supplementary Figure 4B).
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Accordingly, the properties of human Mreg-induced FoxP3+
T cells are most consistent with them being described as iTregs, as
opposed to activated effector T cells, memory T cells or exhausted
T cells. For brevity, ‘Mreg-induced iTreg’ is henceforth shortened
to ‘miTreg’.
Normally, FoxP3 expression by in vitro-generated iTregs
without demethylated TSDR can be easily extinguished by strong
polyclonal activation14. To assess their phenotypic stability and
proliferative potential, miTregs were isolated from allogeneic
cocultures and then re-cultured. Because GARP was not
detectably expressed in FoxP3− T cells, but was expressed at a
low level by most miTregs, it could be used as a surrogate marker
for puriﬁcation of viable cells (Supplementary Figure 4C).
Exponential growth was observed when ﬂow-sorted GARP+
miTregs were re-stimulated in culture using anti-CD3/CD28
beads plus exogenous IL-2 over a 3-week period (Fig. 4c). During
this expansion, FoxP3 expression decayed from 69.6 ± 14.2 to
36.6 ± 5.2% (Fig. 4d). Although the proportion of FoxP3+ T cells
declined as a consequence of re-stimulation, miTregs certainly
did not disappear and their absolute number increased by >250-
fold in all cases. No relevant increase in TSDR demethylation was
detected during the re-stimulation phase (Fig. 4e) indicating that
miTregs did not re-differentiate into nTreg-like cells and that
miTregs were not supplanted by contaminating nTregs. Taken
together, these results indicate miTregs represent a semi-stable
state of T cell activation and are not mere transitory forms.
Various methods for in vitro generation of human FoxP3+
iTregs have been described15, including activation of naive CD4+
FoxP3+
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05167-8
6 NATURE COMMUNICATIONS |  (2018) 9:2858 | DOI: 10.1038/s41467-018-05167-8 | www.nature.com/naturecommunications
T cells in the presence of IL-2 and TGF-β, or activation under
tryptophan-free conditions; however, such iTregs are phenotypi-
cally and functionally different from naturally occurring FoxP3+
Helios− Tregs, which are often called peripheral (p)Tregs to
emphasise this distinction16. To better understand how miTregs
are related to other human iTregs17,18, pTregs, nTregs and non-
Tregs, we assessed expression of 29 Treg-associated markers in
nine comparator T cell populations by ﬂow cytometry (Fig. 4f and
Supplementary Figure 5). Background-subtracted mean ﬂuores-
cence intensity was calculated for each marker for every cell type
from six independent donors: these data were then reduced by
principal component (PC) analysis. PC1 distinguished miTregs
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from other in vitro-derived iTregs, whereas PC2 and PC3
discriminated miTregs from activated T cells, fresh nTreg and
expanded nTreg. In this analysis, miTregs were most similar to
naive T cells and pTregs. Because miTregs exhibited many
differences to other in vitro naive CD4+ iTregs, we infer that
distinct mechanisms must contribute to their differentiation.
Multiple non-redundant mechanisms of miTreg generation.
Enrichment of miTregs appears to be a specialised function of
Mregs because IFN-γ Mφ do not have the same effect (Fig. 2h).
Transwell separation of allogeneic Mregs and T cells in coculture
demonstrated the need for direct physical interaction for Mreg-
driven iTreg development (Fig. 5a). Inhibition of T cell receptor
(TCR) signalling with tacrolimus signiﬁcantly reduced miTreg
induction (Fig. 5b). Blocking B7-mediated signalling with anti-
CD86 or CTLA4-Ig showed that miTreg generation depended
upon CD28 costimulation (Fig. 5c). Neutralisation of IL-2 or IL-
2Rα reduced miTreg generation (Fig. 5d) and rapamycin also
inhibited miTreg development at relatively high concentrations
(Fig. 5e). Despite this role for IL-2 signalling, miTreg enrichment
did not depend upon proliferation (Fig. 5f). Mycophenolic acid
partly blocked miTreg development at concentrations above 100
nM (Fig. 5g), whereas 10 nM dexamethasone strongly suppressed
miTregs (Fig. 5h). Because Mreg-mediated suppression of T cell
proliferation is IDO-dependent, the effect of blocking IDO
activity with 1-methyltryptophan (1-MT) was examined: 1 mM 1-
L-MT signiﬁcantly reduced miTreg development, whereas 1-D-
MT had no effect (Fig. 5i). One mechanism by which IDO pro-
motes Treg differentiation is degradation of tryptophan to
kynurenines, which act as ligands for the aryl hydrocarbon
receptor (AHR)19. No differential expression of AHR was
detected between miTregs and non-Tregs (Fig. 5j). A pan-retinoic
acid receptor antagonist (AGN 193109) effectively suppressed
miTreg generation (Fig. 5k). Blocking Notch signalling with
dibenzazepine, which acts as a γ-secretase inhibitor, impaired
miTreg generation (Fig. 5l). Constitutive secretion of IL-10 by
human Mregs was minimal and LPS-stimulated Mregs released
signiﬁcantly less IL-10 than classically activated macrophages
(Fig. 5m). Neutralisation of IL-10, IL-10Rα or IL-10Rβ had no
effect on miTreg development (Fig. 5n). Mregs constitutively
produced more TGF-β1 than resting macrophages, IFN-γ Mφ or
classically activated macrophages (Fig. 5o) and production was
further enhanced by LPS stimulation. Neutralising TGF-β1 led to
a consistent reduction in miTregs (Fig. 5p) and blocking antibody
against TGF-βRII completely abrogated miTreg generation
(Fig. 5q). Conversely, miTreg generation was enhanced by neu-
tralising antibody against latency-associated peptide (Fig. 5q) or
addition of exogenous TGF-β1 (Fig. 5r). Dose-dependent sup-
pression of miTreg development was observed with two inhibi-
tors of TGF-βRI signalling (Fig. 5s, t). From these experiments, it
is evident that Mreg-mediated generation of iTregs involves
multiple receptor-mediated and soluble factor-mediated interac-
tions that are not unique to Mregs.
T cell activation, IDO activity, retinoic acid receptor ligation
and TGF-β signalling were already known to promote
in vitro differentiation of human iTregs; however, these
factors alone do not account for the unique phenotype of
miTregs (Fig. 4f). Therefore, we asked whether any Mreg-
speciﬁc mechanisms contribute to miTreg differentiation.
Transcriptional proﬁling studies comparing human Mregs
to macrophages in other activation states identiﬁed genes
highly and selectively upregulated in Mregs, including PAEP
(alias PP14 or glycodelin) (Fig. 5u). In Mreg coculture
experiments, antibody blockade of PAEP led to a signiﬁcant
reduction in miTreg generation (Fig. 5v). This example suggests
that other undiscovered mechanisms might contribute to miTreg
differentiation.
Transcriptional proﬁling of Mreg-cocultured T cells. To ﬁnd
novel pathways involved in miTreg development, whole-genome
gene expression-proﬁling studies were conducted (Fig. 6). Mreg-
cocultured and IFN-γ Mφ-cocultured CD4+ T cells were more
similar to one another than to either fresh CD4+ T cells or CD4+
T cells cultured alone; however, substantial differences between
Mreg- and IFN-γ Mφ-cocultured CD4+ T cells were returned by
discriminatory gene analysis (Supplementary Data 1). Treg-
associated genes were among those upregulated in
Mreg-cocultured T cells compared to IFN-γ Mφ-cocultured
T cells—notably, FOXP3, IL2RA, EBI3 and LRRC32 (GARP).
FOXP3 expression was upregulated by Mreg coculture, whereas
key transcriptional regulators of Th1, Th2 and Th17 cell differ-
entiation (ie. TBET, GATA3 and RORC) were not differentially
affected.
One objective of this work was to identify markers and
pharmacodynamic effects that could be used to infer direct
interaction of donor-derived Mregs with recipient T cells after
administration of Mregs to patients. To this end, we next
examined genes that were highly and signiﬁcantly upregulated
Fig. 5 miTreg generation involves multiple non-redundant interactions. a miTreg did not arise when T cells and Mregs were separated using a transwell
insert (n= 6; MW). bmiTreg generation was inhibited in a dose-dependent manner by tacrolimus (n= 3; mean ± sd). cmiTreg generation was inhibited by
anti-CD86 or CTLA4-Ig, but not by anti-CD80 antibodies at 20 μg ml−1 (n= 6; KW). d miTreg generation was inhibited by 20 μg ml−1 anti-IL-2 or anti-IL-
2Rα (n= 6; KW). e miTreg development was reduced by inhibiting mTOR signalling with rapamycin (n= 3; mean ± sd). f CFSE-labelled T cells did not
proliferate during a 5-day coculture with allogeneic Mregs (n= 3). g miTreg generation was partly inhibited by mycophenolic acid (n= 3; mean ± sd).
h miTreg generation was inhibited in a dose-dependent manner by dexamethasone (n= 3; mean ± sd). i miTreg generation was reduced when IDO was
inhibited with 1 mM 1-L-methyltryptophan (1-L-MT) but not with 1 mM 1-D-MT (n= 6; MW). j Aryl hydrocarbon receptor (AHR) was expressed equally by
FoxP3+ miTregs and CD25+ non-Tregs. k miTreg generation was inhibited with 10 μM AGN 193109, a pan-retinoic acid receptor antagonist (n= 6; MW).
l miTreg generation was reduced when Notch signalling was blocked by inhibiting γ-secretase with 1 μM dibenzazepine (n= 6; MW). m Twenty-four-hour
secretion of IL-10 by Mregs and comparator macrophages (n= 6). n Neutralising antibodies against IL-10, IL-10Rα and IL-10Rβ (each at 20 μg ml−1) did not
affect miTreg generation (n= 6; KW). o Twenty-four-hour secretion of TGF-β1 by Mregs and comparator macrophages (n= 6). p A concentration of 20 μg
ml−1 neutralising antibody against TGF-β1 consistently reduced miTreg generation (n= 9; paired t-test; p= 0.002). q miTreg generation was inhibited with
20 μg ml−1 anti-TGF-βRII and signiﬁcantly enhanced by 20 μgml−1 anti-LAP (n= 6; KW). r Addition of 5 ng ml−1 TGF-β1 to Mreg cocultures signiﬁcantly
increased miTreg generation (n= 6; MW). s miTreg generation was reduced in a dose-dependent manner by inhibiting TGF-βRI signalling with SB 25334
(n= 3; mean ± sd). t miTreg generation was reduced in a dose-dependent manner by inhibiting TGF-βRI signalling with R 268712 (n= 3; mean ± sd).
u Relative expression of PAEP mRNA in a panel of nine human comparator macrophages (n= 3; mean ± sd). v miTreg generation was reduced by
20 μg ml−1 antibody against progestagen-associated endometrial protein (PAEP; n= 6; MW)
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by Mreg coculture (Fig. 7a). The 10 most discriminatory
reporters included 5 genes encoding proteins with known
function (CYS1, OXCT2, RET, GNG4 and EBI3), one cell-
surface receptor (butyrophilin-like protein 8; BTNL8), two
predicted proteins of unknown function (SEC14L6 and
C11orf96) and one lincRNA (represented by reporters
A_19_P00316371 and A_19_P00810403). Of these upregulated
genes, BTNL8 stood out as a possible marker of miTregs with
likely functional relevance.
Upregulation of BTNL8 mRNA after Mreg coculture was
corroborated by quantitative PCR (qPCR) using primers that
ampliﬁed both the BTN-like and B7-like variants of BTNL8
(Fig. 7b). Using isoform-speciﬁc primer sets and sequencing of
amplicons, it was determined that Mreg-cocultured T cells
preferentially expressed the B7-like, ~37-kD variant of BTNL8.
Expression of BTNL8 mRNA was not detected in freshly isolated,
human peripheral blood Tregs or conventional CD4+ T cells
(Fig. 7c). However, BTNL8 was highly expressed by peripheral
blood Tregs after polyclonal stimulation and to a lesser extent in
activated non-Tregs. Western blotting using goat α-BTNL8 pAb
(Supplementary Figure 6) revealed stronger expression of the 37-
kD isoform of BTNL8 in Mreg-cocultured T cells compared to
IFN-γ Mφ-cocultured T cells (Fig. 7d). Expression of BTNL8
mRNA was greater in GARP+ miTregs compared to GARP−
non-Tregs (Fig. 7e). BTNL8 protein was detected in miTregs by
ﬂow cytometry after intracellular staining with rabbit α-BTNL8
pAb (Fig. 7f, g). By this method, stronger expression of BTNL8
was found in miTregs than in CD25+ FoxP3− or CD25− non-
Tregs (Fig. 7h). Addition of 10 μg ml−1 BTNL8-Fc fusion protein
to allogeneic cocultures of Mregs and naive CD4+ T cells led to a
small, but consistent increase in miTreg generation (Fig. 7i).
Likewise, addition of 20 μg ml−1 anti-BTNL8 monoclonal anti-
body led to an increase in miTreg generation (Fig. 7j). Taken
together, these results indicate that the 37-kD isoform of
BTNL8 is more highly expressed in activated Treg than resting
Treg or non-Treg, which raises the possibility that
BTNL8 engagement promotes conversion of naive T cells to
miTregs.
Reconstitution experiments were performed in NOD-scid-
gamma (NSG) mice to ascertain whether in vivo administra-
tion of Mregs drives BTNL8 expression in allogeneic human
T cells (Fig. 7j). All animals were given an i.v. injection of 5 ×
106 naive human T cells and were then randomised to receive a
second i.v. injection of 5 × 106 allogeneic Mregs or vehicle only.
Human T cells were recovered from spleen on day 5 after
treatment by positive bead selection of CD3+ cells and end-
point PCR was performed to assess BTNL8 expression. BTNL8
was detected in two of three Mreg-treated recipients, but not in
untreated recipients. We conclude that BTLN8 may be a
valuable marker of human peripherally induced Tregs
and could potentially be used for monitoring miTregs in
patients.
Mreg-induced Tregs express TIGIT. Having identiﬁed BTNL8
as a possible marker of miTregs, we asked whether other BTN
and BTNL family members were differentially regulated in these
cells. No signiﬁcant differences in expression of other BTN or
BTNL family members were observed between Mreg-cocultured
CD4+ T cells and controls (Supplementary Figure 7A). The
microarray data set was then screened more broadly for differ-
ential expression of other IgSF co-inhibitory receptors. T cell
immunoreceptor with Ig and ITIM domains (TIGIT) mRNA was
more highly expressed in Mreg-cocultured T cells compared to
control conditions (Supplementary Figure 7B). A greater pro-
portion of miTregs expressed cell-surface TIGIT than non-Tregs
(Fig. 8a). IL-10 production by Mreg-cocultured T cells was
essentially restricted to TIGIT+ T cells (Fig. 8b). Mreg-mediated
induction of TIGIT in CD4+ T cells was signiﬁcantly more
effective than TIGIT induction by other monocyte-derived
macrophages and DCs (Fig. 8c). Expression of TIGIT by naive
T cells was induced by Mreg coculture but not by anti-CD3/
CD28 stimulation (Fig. 8d) so we next asked whether miTregs are
predominantly TIGIT+ because they derive from pre-exisiting
TIGIT+ non-Tregs. Prior to coculture with Mregs, naive CD4+
T cells were separated into TIGIT+ and TIGIT− fractions by
magnetic bead selection: TIGIT+ T cells gave rise to signiﬁcantly
more miTregs than either unfractionated naive T cells or TIGIT−
T cells (Fig. 8e). A greater proportion of low-tryptophan-
induced iTregs expressed TIGIT compared to naive CD4+
T cells, TGF-β-induced iTregs or TGF-β plus all-trans retinoic
acid (ATRA)-induced iTregs (Fig. 8f); therefore, we hypothesised
that TIGIT induction by Mregs might be partly explained by IDO
activity. Addition of 1-L-MT to cocultures, but not 1-D-MT, sig-
niﬁcantly reduced TIGIT+ T cell frequency (Fig. 8g). Mregs
expressed both CD112 (PVRL2) and CD155 (PVR), which are
ligands of TIGIT (Fig. 8h). These ﬁndings show that Mregs
induce TIGIT expression in allogeneic T cells through an IDO-
dependent mechanism, as well as providing TIGIT ligands, which
might explain the high level of IL-10 production by miTregs.
To investigate whether allogeneic mouse Mregs induced TIGIT
expression in CD4+ T cells in vivo, mouse Mregs were generated
from C3H mice and administered by i.v. injection to BALB/c
recipients at a dose of 5 × 106 cells per animal. Five days after
treatment, splenic CD4+ T cells were isolated by magnetic bead
–3.0
Mreg coculture
IFN-γ Mϕ coculture
Fresh CD4+ T cells
Cultured CD4+ T cells
Genes up-regulated in Mreg-cocultured CD4+ T cells
0 3.0
Fig. 6 Identiﬁcation of novel markers associated with miTregs. To better characterise the phenotype of miTregs, whole-genome gene expression-proﬁling
studies by microarray were performed. Mregs and IFN-γMφ were generated from CD14+monocytes of ﬁve healthy donors. Seven days later, CD3+ T cells
were isolated from ﬁve unrelated donors and split into two lots: from the ﬁrst lot, a pure population of fresh CD4+ T cells was obtained by ﬂow-sorting and
total RNA was extracted; the second lot of T cells were added into direct coculture with allogeneic Mregs or IFN-γ Mφ at a 1:1 ratio for 5 days, or were
cultured alone without stimulation for 5 days. After culture, CD4+ T cells were ﬂow-sorted and total RNA was extracted. A microarray data set was then
generated that comprised four cell populations from ﬁve independent donors produced by single-colour hybridisations. The heatmap shows a hierarchical
clustering of reporters returned by one-way ANOVA that were signiﬁcantly (p < 0.01 after Benjamini-Hochberg correction for multiple testing) and highly
differentially (>20-fold) regulated between any two of the T-cell populations (red: upregulation; green: downregulation)
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separation and reverse transcription (RT)-qPCR for Tigit and Il10
mRNA was performed. Mice treated with allogeneic Mregs
expressed signiﬁcantly higher levels of both transcripts (Fig. 8i). A
reconstitution experiment was then performed in NSG mice to
test whether human Mregs could induce TIGIT and IL-10
expression by allogeneic human T cells in vivo (Fig. 8j). Human
CD25+ FoxP3+ Treg frequencies were higher in Mreg-treated
mice than vehicle-only controls, although proportions of TIGIT+
CD4+ T cells were similar (Fig. 8k). Serum levels of human IL-10
were signiﬁcantly higher in Mreg-treated recipients compared to
controls (Fig. 8l). These data indicate that allogeneic Mregs were
capable of inducing TIGIT+ Tregs in this human-into-mouse
model, which presumably involved direct allorecognition of
Mregs by T cells.
Acute increase of TIGIT+ Tregs after Mreg treatment. As early
as 2008, prospective living-donor kidney transplant recipients
were given crude Mreg preparations in the expectation of redu-
cing long-term dependence on immunosuppressive drug treat-
ment10. These ﬁrst-in-man cases demonstrated the clinical
feasibility of Mreg treatment in kidney transplantation, yielded
important safety information and provided hints of a beneﬁcial
immunological effect. Following signiﬁcant technical reﬁnements,
a good manufacturing practice-compliant production process for
manufacturing an Mreg-containing cell product, which is known
as ‘Mreg_UKR’, was established (Fig. 9a)11. Mreg_UKR is under
investigation as a means to safely minimise maintenance immu-
nosuppression after kidney transplantation in the ONEmreg12
trial. This phase-I/II study provides an opportunity to study the
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inﬂuence of allogeneic Mreg treatment upon recipient T cell
responses. According to protocol, ONEmreg12 trial participants
are treated with donor-derived Mregs on day 7 prior to trans-
plantation (Fig. 9b). In the peri-operative phase, patients received
standard-of-care, triple immunosuppressive therapy, except
basiliximab (anti-IL-2Rα) induction therapy is omitted.
Altogether Treg frequencies were monitored in ﬁve allogeneic
donor–recipient pairs before Mreg infusion and 1 day prior to
living-donor kidney transplantation, including two patients
recruited to ONEmreg12 and three participants of earlier clinical
trials10. All ﬁve patient pairs were mismatched at one or more
HLA-A, -B or -DR locus. In four out of ﬁve patients, an increase
in peripheral blood CD4+ CD25+ CD127int Treg frequency was
observed (Fig. 9c). A single patient enrolled in the ONEmreg12
trial presented an opportunity to assess peripheral blood
frequencies of TIGIT+ Tregs at close intervals during the week
after Mreg infusion. This high-granularity sampling revealed an
increase in Treg frequency during the ﬁrst 18 h after Mreg
infusion, which peaked by the third day (Fig. 9d). Notably, this
increase was primarily due to an increase in TIGIT+ Treg
frequency (Fig. 9e). This ﬁrst description of TIGIT+ Treg
induction after Mreg treatment must be conﬁrmed in more
patients; however, it is promisingly consistent with our preclinical
experiments.
Long-term enrichment of TIGIT+ Tregs after Mreg therapy.
Serial TCR spectratyping was performed in one patient (CA) after
treatment with Mregs10. This led to identiﬁcation of an oligo-
clonal or monoclonal expansion of TCRVβ13.1-expressing T cells
that ﬁrst emerged after Mreg treatment and persisted until at least
168 days post transplant (Fig. 10a). The kinetics of this T cell
expansion suggested a donor alloantigen-speciﬁc response. CA
was followed-up at ~7 years post transplantation, when graft
function was stable and no rejection episodes had occurred under
very low-dose tacrolimus monotherapy (3 mg Advagraf every
second day) with trough levels of <2 ng ml−1. Expansion of
TCRVβ13.1+ T cells was still detectable at the time of follow-up
and, more surprisingly, we found the TCRVβ13.1+ CD4+ T cell
compartment was enriched for TIGIT+ FoxP3+ Tregs.
These data are interpreted as evidence of a donor-speciﬁc
expansion and long-term persistence of TIGIT+ TCRVβ13.1+
Tregs.
Discussion
Cell-based tolerance-promoting therapies are a radical departure
from conventional immunosuppressive treatment of solid organ
transplant recipients1. As with any drug treatment, understanding
the pharmacological character of cell-based therapies is
vital for predicting effectiveness and anticipating adverse reac-
tions20. In this study, Mregs converted a high proportion of
directly cocultured, allogeneic CD4+ T cells into IL-10-secreting
miTregs. These miTregs were not simply activated T cells,
exhausted T cells21 or TEMRA. miTregs did not derive from nTreg
because they arose in Treg-depleted naive CD4+ T cell cultures
and TSDR demethylation was minimal22. Administration of
mouse Mregs to allogeneic recipients increased Tigit and Il10
mRNA expression by splenic CD4+ T cells in vivo. In a human-
into-mouse reconstitution model, human Mregs also converted
allogeneic CD4+ T cells to IL-10-producing iTregs. These pre-
clinical observations led to the discovery that Mreg treatment of
prospective kidney transplant recipients elicited TIGIT+ Treg
responses. Overall, our study supports the idea that miTreg could
play a mechanistic role in the clinical effects of Mreg therapy.
miTreg development involves multiple, non-redundant inter-
actions that are not necessarily speciﬁc to Mregs, but together
confer Mregs with specialised regulatory function. We found a
prominent role for IDO in miTreg differentiation and TIGIT
expression, but this does not sufﬁciently explain the iTreg-
inducing capacity of Mregs. In our system, miTreg differentiation
required T cell activation and was inﬂuenced by TGF-β, RA,
PAEP and BTNL8 signalling. Looking for further mechanisms,
we annotated reporters upregulated in Mreg-cocultured CD4+
T cells according to Gene Ontology pathways (Supplementary
Data 2). This revealed enrichment of genes associated with Notch
signalling23. Using a γ-secretase inhibitor, the involvement of
canonical Notch signalling was conﬁrmed. Beyond these veriﬁed
mechanisms, expression-proﬁling data suggest possible involve-
ment of vitamin D, arginase and negative costimulatory pathways
in miTreg development, stabilisation or survival. Hence, the
regulatory activity of Mregs cannot be explained by a single,
Mreg-speciﬁc mechanism: it reﬂects the net effect of many
pathways, some of which may be common to other myeloid
APCs. It has not escaped our attention that Mreg:T cell coculture
could be used as a functional screening assay to discover novel
mechanisms of iTreg development or identify drugs that inﬂu-
ence iTreg differentiation24.
PAEP, which is also known as glycodelin, is a 28-kDa glyco-
protein produced by secretory and decidualised endometrium in
women and by seminal vesicle epithelium in men. PAEP plays
critical roles in placental development and establishment of
fetomaternal tolerance in early pregnancy25. Speciﬁcally, PAEP
controls the number and effector functions of decidual T cells,
favouring a Th2-type environment through selective apoptosis of
Fig. 7 BTNL8 is expressed by miTregs. a Discriminatory gene analysis identiﬁed genes upregulated in Mreg-cocultured CD4+ T cells compared to controls.
The 10 most highly upregulated reporters in allogeneic Mreg-cocultured CD4+ T cells compared to IFN-γ Mφ-cocultured CD4+ T cells are shown (n= 5;
median ±MADM). b qPCR for BTNL8 mRNA in CD4+ T cells cocultured with allogeneic Mregs or IFN-γ Mφ, CD4+ T cells cultured alone and freshly
isolated CD4+ T cells (n= 9; mean ± SEM; KW). c Human peripheral blood T cells were ﬂow-sorted for CD3+CD4+CD25+CD127int Tregs and CD3+CD4
+CD25−CD127+ non-Tregs. BTNL8 mRNA expression was not detected in unactivated Treg or conventional T cells, but was induced by stimulation with
αCD3/αCD28 beads for 5 days (n= 4; MW). d Western blot for BTNL8 using goat α-BTNL8 (Santa Cruz, sc-245053) to compare T cells cocultured with
allogeneic Mregs or IFN-γ Mφ. A band corresponding to BTNL8 was detected at 37 kD. e BTNL8 mRNA was more highly expressed by GARP+ miTregs
than GARP− non-Tregs (n= 6). f Detection of BTNL8 expression in Mreg-cocultured T cells by ﬂow cytometry after intracellular staining with rabbit α-
BTNL8 pAb (LSBio #C453018) against aa 161–210. Histogram is gated on live CD3+ CD4+ CD8− CD25+ FoxP3+ single events. g Pre-incubation of rabbit
α-BTNL8 pAb with speciﬁc peptide (LSBio #E18020) blocked detection of BTNL8, whereas a non-speciﬁc peptide corresponding to the N terminus of
BTNL8 (#E18019) had no effect. h By ﬂow cytometry, BTNL8 appeared to be expressed by all Mreg-cocultured CD4+ T cells, but miTregs expressed higher
levels of BTNL8 than CD25+ FoxP3− or CD25− FoxP3− non-Tregs (n= 3). i Compared to recombinant human Fc (rhFc), addition of 10 μg ml−1 BTNL8-Fc
fusion protein enhanced miTreg generation (n= 8; MW). j A concentration of 20 μg ml−1 α-BTNL8 rabbit mAb (R&D #2187B) enhanced miTreg
generation compared to isotype control (n= 9; MW). k NOD-scid-gamma (NSG) mice were reconstituted with 5 × 106 naive human CD4+ T cells and
then treated with either 5 × 106 allogeneic Mregs (n= 3) or vehicle only (n= 3). Five days after cell transfer, splenic human T cells were recovered by
bead-sorting, and end-point PCR for BTNL8 mRNA was performed
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Th1 cells26. Within the haematopoietic system, PAEP is expressed
by erythroid precursors, but not by mature erythrocytes, throm-
bocytes, mononuclear phagocytes or lymphocytes27. PAEP
secretion is presently the only known mechanism of miTreg
induction exclusive to Mregs.
This study discovered the B7-like isoform of BTNL8 as
potentially useful marker of activated miTregs. BTNL8 is an
intriguing receptor from a basic immunological perspective28.
The butyrophilin (BTN) and butyrophilin-like (BTNL) proteins
are B7-related receptors that serve as negative regulators of innate
and adaptive immune responses29. The human genome encodes
four BTNL genes (BTNL2, -3, -8 and -9) of which only BTNL2
and BTNL9 have orthologues in mice30. Ig-fusion proteins of
mouse Btnl1, Btnl2 and Btnl9 exert T cell-suppressive properties
%
 M
ax
.
a
d e f
ihg
j k l
b c
TIGIT
TI
G
IT
Interleukin-10
CD112
(PVRL2)
CD155
(PVR)
0
0
103 104 105
105
104
47.4%
26.7% 5.6%
20.4%
50
60 40 20
15
10
5
ns ns
*
** ** **
0
Δ = 20.7%, p = 0.029
Day 0
Day 5
30
20
10
0
50
40
30
50 3.0 2.0
1.5
1.0
0.5
0.0
20 **
15
10
5
0
T c
ells
 al
on
e
Mr
eg
-tre
ate
d
2.0
1.0
0.0
Un
tre
ate
d
Mr
eg
-tre
ate
d
Un
tre
ate
d
Mr
eg
-tre
ate
d
40
30
20
10
0
20
10
0
Pre
-cu
ltu
re
Un
tre
ate
d
1-D
-M
T
1-L
-M
T
Mr
eg
 co
cul
tur
ed
Un
stim
ula
ted
αC
D3
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
40
30
20
10
0
Mr
eg
CD
3+
Na
ive
 CD
4+
Na
ive
 CD
4+
 TI
GIT
+
Na
ive
 CD
4+
 TI
GIT
–
CD
3+
Na
ive
 CD
4+
Na
ive
 CD
4+
 TI
GIT
+
Na
ive
 CD
4+
 TI
GIT
–
Na
ive
 CD
4+  
T c
ells
TG
F-β
-
ind
uc
ed
 Tr
eg
TG
F-β
 
+ 
AT
RA
-in
du
ce
d T
re
g
Lo
w 
try
pto
ph
an
-in
du
ce
d T
re
g
Re
stin
g M
ϕ
IFN
-γ M
ϕ
IFN
-γ +
 LP
S M
ϕ
IL-
4 M
ϕ
GC
 M
ϕ
Im
ma
tur
e D
C
Ma
tur
e D
C
TI
G
IT
+ 
fre
qu
en
cy
 w
ith
in
CD
4+
 T
 c
el
l p
op
ul
at
io
n 
(%
)
TI
G
IT
+
 
fre
qu
en
cy
 w
ith
in
CD
4+
 T
 c
el
l p
op
ul
at
io
n 
(%
)
TI
G
IT
+
 
fre
qu
en
cy
 w
ith
in
CD
4+
 T
 c
el
l p
op
ul
at
io
n 
(%
)
R
el
at
ive
 T
ig
it 
m
R
N
A
ex
pr
es
sio
n
R
el
at
ive
 II
10
 
m
R
N
A
ex
pr
es
sio
n
Se
ru
m
 IL
-1
0 
(pg
/m
l)
m
iTr
e
g 
fre
qu
en
cy
 (%
)
iTr
e
g 
(%
)
103
102 103 104 105
0
0
102 103 104 1050
Human cells
M
re
g-
tre
at
ed
re
ci
pi
en
ts
Fo
xP
3
TI
G
IT
CD25 CD25
T 
ce
lls
a
lo
ne
Allogeneic naive
CD4+ T cellsMreg
5 days
NSG mouse Serum IL-10
Splenic Treg
0 0
102 103 104 105
105
104
103
102
101
105
104
103
102
105
104
103
102
105
104
103
102
0
0
101
101 102
5.93%
11.20%
9.79%
1.86%
103 104 105
101 102 103 104 105
101 102 103 104 105
101 102 103 104 105
0
FoxP3+
FoxP3–
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05167-8
12 NATURE COMMUNICATIONS |  (2018) 9:2858 | DOI: 10.1038/s41467-018-05167-8 | www.nature.com/naturecommunications
in vitro through unknown counter-receptors31–33; however,
functional characterisation of human BTNL family members is
sparse. BTNL8 is a type-I membrane protein with an extracellular
region comprising an IgV and IgC domain28. Various isoforms of
BTNL8 have been reported, including a 57-kD protein incor-
porating an intracellular B30.2 domain, which is lacking from the
37-kD isoform. Expression of both variants in enterocytes34,
neutrophils and eosinophils35 has been reported, but not T cells,
B cells, natural killer (NK) cells or monocytes30,36. Here the 37-
kD isoform of BTNL8 was highly upregulated in Mreg-cocultured
CD4+ T cells, especially the GARP-selected miTreg-enriched
fraction. Recently, a human BTNL8-Fc fusion protein was shown
to bind an unknown receptor on resting T cells that co-stimulated
anti-CD3-induced activation35. In our experiments, BTNL8-Fc
and α-BTNL8 antibody increased miTreg generation. We hypo-
thesise that miTregs stimulate bystander naive T cells through
BTNL8, thereby amplifying iTreg generation.
TIGIT is a co-inhibitory receptor of the CD28 family37 that is
expressed by NK cells38, activated T cells, memory T cells39,
follicular T helper cells40 and Treg subsets41–43. Mregs strongly
induced TIGIT+ T cells through a partly IDO-dependent
mechanism. The TIGIT gene is a direct target of FoxP3, which
accounts for TIGIT expression in nTregs, but does not explain
how TIGIT expression could precede FoxP3 induction in Mreg-
cocultured T cells. TIGIT competes against the costimulatory
receptor CD226 (DNAM-1)44 for ligation by CD155 or CD11245.
After Mreg coculture, the proportion of CD226+ TIGIT+ iTregs
was higher than CD226− TIGIT+ iTregs, but the functional
signiﬁcance of this is unknown. Engagement of TIGIT on con-
ventional T cells delivers an ITIM-mediated signal that blocks T
cell proliferation and effector functions46 by downregulating
components of the TCR signalling cascade47. At the same time,
TIGIT upregulates anti-apoptotic molecules and receptors for IL-
2, IL-7 and IL-15, thereby promoting survival of functionally
anergised T cells. In nTregs, TIGIT engagement upregulates IL-10
production and Fgl2 secretion, which preferentially suppresses
Th1 and Th17 responses48. IL-10 expression by Mreg-cocultured
T cells closely correlated with TIGIT expression. CD155 ligation
by TIGIT delivers tolerising signals to APC49, which might
contribute to the stability of Mreg regulatory function50.
Increased TIGIT+ Treg frequency in Mreg-treated patients
speaks to the likely importance of TIGIT for the clinical effects of
Mreg therapy.
In theory, donor-derived Mregs might inﬂuence antigen-
speciﬁc recipient T cell responses in two main ways, which are
not mutually exclusive51: ﬁrst, Mregs might give up alloantigen52
to recipient APC, which then modify recipient T cell responses3;
second, infused Mregs might interact directly with recipient
T cells to anergise or delete antigen-speciﬁc effector T cells53 or
induce Tregs54. The tolerogenic properties of i.v. alloantigen are
well-known55,56 and it seems probable that reprocessing of Mreg-
derived antigens by recipient APC (via indirect or semi-direct
pathways) contributes to the therapeutic beneﬁt of Mreg treat-
ment. The suggestion that Mregs might also interact directly with
recipient T cells to suppress or regulate their reactivity57 is con-
troversial because others have shown that recipient cDC are
indispensible for the tolerising effect of donor-derived immature
DC treatment in some systems58. Notably, Wang et al. used
CD11c-DTR bone marrow chimeras to show that pre-transplant
administration of Vit.D3-treated, ‘maturation-resistant’ DC
(MRDC) did not prolong allograft survival after deletion of
recipient DC59. In this model, donor-strain MRDCs were quickly
eliminated by NK cells, leading to their uptake by recipient DCs
as apoptotic remnants. Alloantigen-loaded recipient DCs then
controlled alloreactive T cell responses through abortive
activation.
It is clear that all myeloid APC are not equally susceptible to
rejection through innate and adaptive mechanisms60,61. Toler-
ance of solid organ transplants is often associated with long-term
persistence of donor-derived mononuclear phagocytes in lym-
phoid and non-lymphoid tissues of the recipient57,62–67. Whether
these residual DCs and macrophages contribute to allograft tol-
erance or are a mere epiphenomenon is not resolved; however,
their engraftment implies escape from rejection. Earlier cell-
tracking experiments in immunocompetent mice showed survival
of allogenic and isogeneic Mregs in non-immunosuppressed
recipients was very similar12, so it seems rejection did not limit
the lifespan of Mregs. Likewise, in humans, HLA-haploidentical
Mregs administered by central i.v. infusion remained viable over
at least 30 h10. Because a detectable fraction of ex vivo-generated
allogeneic Mregs migrates to, and survives for days or weeks, at
sites where interaction with recipient T cells could conceivably
occur then there is no a priori reason why donor-derived Mregs
could not initiate direct-pathway recipient iTreg responses.
Even a transient expansion of allospeciﬁc iTregs could bias
recipient T cell responses in favour of allograft acceptance. We
imagine that miTregs could contribute to long-term acceptance of
allografts in two ways. First, direct iTregs could facilitate indirect
nTreg responses, perhaps by modifying recipient DC68,69 to
initiate a feed-forward loop of ‘infectious tolerance’70. Notably,
immature mo-DCs exposed to Mreg-cocultured T cells were
relatively refractory to maturation with TNFα. The capacity of
these ‘tolerised’ DC to support a second wave of Tregs is currently
being investigated. A second possibility is that miTregs survive
Fig. 8Mreg generation of IL-10-producing, TIGIT+ miTregs is IDO-dependent. Microarray data indicated higher expression of TIGIT (WUCAM, VSTM3) in
Mreg-cocultured CD4+ T cells compared to control conditions. a Flow cytometry conﬁrmed TIGIT expression by most miTregs and a high proportion of
Mreg-cocultured non-Tregs (representative of n= 6). b After Mreg coculture, the majority of IL-10-producing CD4+ T cells were TIGIT+ (representative of
n= 6). c Mreg coculture was signiﬁcantly more effective in inducing TIGIT expression in CD4+ T cells than coculture with differently activated monocyte-
derived macrophages or mo-DCs (n= 6; ANOVA). d TIGIT expression by CD4+ T cells was induced by Mreg coculture, but not by polyclonal T-cell
activation with αCD3/αCD28 beads (n= 3; paired t-test). e Mregs preferentially convert naive CD4+ non-Tregs into miTregs (n= 6; MW). f Comparing
different subsets of in vitro-derived human iTregs revealed highest TIGIT expression in low-tryptophan iTregs (n= 6; ANOVA) and suggested a role for
IDO in Mreg-induced TIGIT expression. g Mreg-induced TIGIT expression was inhibited with 1 mM 1-L-methyltryptophan (1-L-MT) but not 1 mM 1-D-MT
(n= 6; MW). hMregs expressed TIGIT ligands CD155 (PVR) and CD112 (PVRL2). i BALB/c mice received either 5 × 106 C3H strain Mregs by intravenous
injection (n= 10) or vehicle only (n= 9). Five days later, splenic CD4+ T cells were isolated and expression of Tigit and Il10 mRNA was assessed by qPCR.
j Induction of TIGIT+ Tregs by allogeneic human Mregs in vivo was investigated using an immunodeﬁcient (NSG) mouse model. NSG mice received either
i.v. injection of 5 × 106 human naive CD4+ T cells alone (n= 6) or i.v. injection of 5 × 106 human naive CD4+ T cells plus a separate i.v. injection of 5 × 106
allogeneic human Mregs (n= 6). After 5 days, serum levels of human IL-10 and splenic human TIGIT+ Treg frequencies were assessed. k Human Mreg-
treated, T-cell-reconstituted NSG mice exhibited higher splenic Treg frequencies and somewhat higher TIGIT+ CD4+ T-cell frequencies. l Serum human IL-
10 levels were signiﬁcantly higher in human Mreg-treated, T-cell-reconstituted NSG mice than controls
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long term and continue to exert a suppressive activity. This
hypothesis is supported by the surprising discovery of persistently
elevated of Vβ13.1+ TIGIT+ Treg numbers in patient CA. Recent
reports indicate that peripherally induced FoxP3+ Tregs can be
stabilised in phenotype and function by TSDR region demethy-
lation. We are currently exploring whether TSDR demethylation
in miTregs can occur in vitro or in vivo.
As a translational therapy, understanding the possible inter-
actions of therapeutically applied Mregs with recipient T cells is
crucial. The new mechanistic insights presented in this article
provide a pharmacological rationale for applying Mreg_UKR
therapy in allogeneic solid organ transplantation and other T cell-
mediated diseases.
Methods
Generation of human monocyte-derived cells. Human Mregs and other
monocyte-derived cell types were generated from CD14+ monocytes according to
previously described methods7. Step-by-step protocols are available through Pro-
tocol Exchange71. Human Mregs and IFN-γ Mφ were generated from peripheral
blood leucocytes obtained as a by-product of thrombocyte collection from healthy
donors. CD14+ monocytes were then isolated from Ficoll-prepared peripheral
blood mononuclear cells by positive selection with anti-CD14 microbeads (Mil-
tenyi, Bergisch-Gladbach) and were plated in six-well Cell+ plates (Sarstedt,
Nümbrecht) at 106 cells per well in RPMI-1640 (Lonza, Cologne) supplemented
with 10% heat-inactivated, male-only human AB serum (Lonza), 2 mM Glutamax
(Invitrogen, Karlsruhe), 100 Uml−1 penicillin (Lonza), 100 μg ml−1 streptomycin
(Lonza), and recombinant human M-CSF (rhM-CSF; R&D Systems, Wiesbaden-
Nordenstadt) at 25 ng ml−1 carried on 0.1% human albumin (CSL-Behring, Hat-
tersheim-am-Main). On day 6 of culture, cells were stimulated for a further 18–24
h with 25 ng ml−1 rhIFNγ (Chemicon, Billerica, MA). IFN-γ Mφ were
generated by cultivating CD14+ monocytes under identical conditions to
Mregs except that human serum was replaced with 10% heat-inactivated
foetal calf serum (Biochrom, Berlin). Step-by-step protocols for generating
other human monocyte-derived macrophages and mo-DCs are available
through Protocol Exchange71. Phagocytosis of pHrodo Red-labelled, ﬁxed E. coli
by Mregs and classically activated macrophages was quantiﬁed at intervals over a 9-
h period according to the manufacturer’s instructions (ThermoFisher Scientiﬁc,
CA).
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Fig. 9 Changes in peripheral blood Treg numbers after Mreg_UKR administration. a An example of Mreg_UKR manufactured under clean-room conditions.
For the pharmaceutical release of Mreg_UKR products, the identity of Mreg cells is speciﬁed according to CD14, CD16, CD80, CD86, CD85h and CD258
expression. It is speciﬁed that impurity of Mreg_UKR products with CD3+ T cells must be ≤1%. It is further speciﬁed that Mreg cells must upregulate IDO
expression as a marker of potency. DHRS9 expression is not speciﬁed as a product-release criterion; however, Mreg cells contained in Mreg_UKR products
uniformly express DHRS9. b One week prior to living-donor kidney transplantation, patients in the ONEmreg12 trial are treated with a single dose of 2.5–7.5
× 106 viable Mregs per kg by central i.v. infusion under cover of mycophenolate mofetil (MMF) 250mg BD. One day prior to kidney transplantation,
patients receive MMF 1 g BD and tacrolimus (Tac) treatment commences at a target serum trough level of 3–12 ng ml-1. Patients receive an intraoperative
steroid bolus, but no basiliximab (anti-IL-2Rα) induction therapy. c CD25+ CD127int Treg frequencies in peripheral blood of Mreg-treated patients assessed
prior to Mreg infusion and 1 day before transplantation. Results from ﬁve patients are shown, including two participants of the TAIC-II Study whose cases
were previously reported elsewhere. d In the case of patient C3157, serial blood samples were collected for measurement of CD4+ CD25+ FoxP3+ Tregs
prior to Mreg infusion and at close intervals over the 6 days before transplantation (values represent mean ± sd of replicate stainings). e The observed
increase in peripheral blood Treg frequency in patient C3157 could be mainly attributed to an increase in TIGIT+ Tregs
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Coculture of human Mregs or IFN-γ Mφ with T cells. On day 7 of culture, Mreg
and IFN-γ Mφ medium was exchanged with serum-free X-VIVO 10 medium
(Lonza) supplemented with 2 mM Glutamax and 25 ng ml−1 rhM-CSF. Magnetic
bead-sorted CD3+ T cells (CD3 Microbeads, Miltenyi) or naive CD4+ T cells
(Naive CD4+ T Cell Isolation Kit II, Miltenyi) were added to macrophages at
speciﬁed suppression:responder ratios for 5 days. Cocultures were performed either
in six-well Cell+ plates at 106 Mreg in 3 ml per well or in sterile, lidded ﬂow
cytometry tubes (Falcon, Amsterdam) at 2 × 105 Mreg in 1 ml per tube. Inserts with
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0.4 μm pores were used for transwell experiments (Greiner-BioOne, Frick-
enhausen). Pharmacological inhibitors were added to cocultures as indicated
(Supplementary Table 1).
In vitro-derived human iTregs and expanded human nTregs. Following pro-
tocols adapted from the literature, three alternative preparations of in vitro-derived
human iTregs were differentiated from bead-sorted human CD4+ naive T cells
(Naive CD4+ T Cell Isolation Kit II, Miltenyi) grown in round-bottomed 96-well
plates at 1.2 × 105 cells per well. ‘Low-tryptophan iTregs’ were generated over
5 days in tryptophan-free medium (PAN-Biotech, Aidenbach, Germany) supple-
mented with 10% dialysed heat-inactivated human AB serum, 100 Uml−1 peni-
cillin, 100 µg ml−1 streptomycin, 4 µM tryptophan (Sigma-Aldrich) and 300 IU IL-
2 ml −1 (Miltenyi)18. On day 0, 100 µl cultures were stimulated with CD3/CD28
MACSi-beads (Miltenyi) and 10 µM each of L-kyneurinine, quinolic acid/2,3 pyr-
idinedicarboxilyc acid, anthranilic acid, 3-hydroxy-anthranilic acid and 3-hydroxy-
DL-kyneurinine (Sigma-Aldrich). On day 2, 100 µl supplemented medium con-
taining 20 µM each of the same mixture of kynurenines was added per well. ‘TGF-
β-induced iTregs’ were generated in X-Vivo 10 medium (Lonza) supplemented
with 2 mM GlutaMax, 300 IU IL-2 ml −1 and 5 ng ml−1 TGF-β1 (R&D Systems)17.
On day 0, 100 µl cultures were stimulated with CD3/CD28 MACSi-beads. On day
2, 100 µl supplemented medium was added to each well. ‘ATRA+ TGF-β-induced
iTregs’ were cultured as TGF-β-induced iTregs except that medium was also
supplemented with 10 nM ATRA (Sigma-Aldrich)17. Expanded human nTregs
were generated from bead-sorted CD4+ CD25+ T cells (CD4+CD25+ Regulatory
T Cell Isolation Kit, Miltenyi) cultured in X-Vivo 10 medium supplemented with
2 mM GlutaMax and 300 IU IL-2 ml −1. On day 0, 100 µl cultures were stimulated
with CD3/CD28 MACSi-beads. On day 2, 100 µl supplemented medium was added
to each well. ‘Activated CD4+ T cells’ were generated from bead-sorted naive
CD4+ T cells cultured in X-Vivo 10 medium supplemented with 2 mM GlutaMax
and 300 IU IL-2 ml −1. On day 0, 100 µl cultures were stimulated with CD3/CD28
MACSi-beads. On day 2, 100 µl supplemented medium was added to each well.
Flow cytometry. Detailed, step-by-step protocols for ﬂow cytometry-based ana-
lyses are available through Protocol Exchange72. Brieﬂy, surface staining was
performed at 4 °C in DPBS/1% BSA/0.02% NaN3/10% FcR-block (Miltenyi) for
30 min. FoxP3 Fixation-and-Permeabilization buffers (eBioscience, Frankfurt) were
used for intracellular staining. Antibodies are listed in Supplementary Table 2.
Dead cells were excluded with Fixable Viability Dye eFluor506 or 7-AAD
(eBioscience). Data were collected with a Canto-II cytometer (BD Biosciences)
running Diva version 6.1.3 (BD) or Navios cytometer (Beckman Coulter, Krefeld,
Germany). Clinical data were collected with a qualiﬁed Navios cytometer running
Beckman Coulter clinical software version 1.3. Analyses were performed with
Flowo (v7.6.5) or Kaluza 1.1 (Beckman Coulter).
Western blotting and immunoprecipitation. Protein G-Plus sepharose (Sigma-
Aldrich) was used to immunoprecipitate BTNL8. SDS-polyacrylamide gel elec-
trophoresis and immunoblotting were performed according to conventional
methods. Uncropped western blotting images were included in Supplementary
Figure 8.
TSDR methylation analysis. CD4+ T cells were positively isolated by magnetic-
activated cell sorting. Genomic DNA was extracted with the QIAamp DNA blood
mini-kit and bisulﬁte-treated (EpiTect, Qiagen) before real-time PCR quantiﬁca-
tion of Foxp3 TSDR.
Quantitative reverse transcription-PCR. SuperScript-III (Invitrogen) was used
for reverse transcription. Quantitative reverse transcription-PCR was performed
with a LightCycler™ real-time PCR system using the FastStart DNA Master SYBR
Green I kit (Roche-Diagnostics, Penzberg) and Quantitect primers (Qiagen) listed
in Supplementary Table 3. Gene expression was normalised against expression of
RPL13A and GAPDH. PCR speciﬁcity was conﬁrmed by amplicon sequencing
(MWG-Biotech, Ebersberg).
Microarrays. Highly puriﬁed populations of CD4+ or CD8+ T cells were isolated
using a FACS-Aria ﬂow-sorter (BD Biosciences). Total RNA was extracted using an
RNeasy-Plus Mini-Kit (Qiagen, Hilden). Assessment of RNA quality, labelling and
hybridisation to 8 × 60K Agilent Whole-Human-Genome-Oligo-Microarrays was
performed according to published methods12. Fluorescence signals from hybridised
microarrays were detected using Agilent’s Microarray Scanner System (G2505C,
Agilent-Technologies, Palo Alto). The Agilent Feature Extraction Software 10.7.3.1
was used to extract the microarray image ﬁles. Background-corrected intensity
values were quantile-normalised and log2-transformed. Only reporters with at least
three valid signal intensity values in at least one sample group were considered. For
visualisation in heatmap format, the log2 intensity values were median-centred for
each reporter. One-way analysis of variance (ANOVA) was performed using
GeneSpring-GX v.11.5.1 (Agilent).
Statistics. Signiﬁcance tests and curve-ﬁtting were performed with GraphPad or
SPSS® software. As indicated, Mann–Whitney, Kruksal–Wallis, t-tests (two-tailed,
equal variances; paired where appropriate) or one-way ANOVA was used for tests
of signiﬁcance. Marker expression was estimated in ﬂow cytometry experiments by
calculating background (isotype)-subtracted geometric mean ﬂuorescence inten-
sities. Values ≤ 0 were set to 1. Data were log10-transformed and expression of each
marker was standardised. PC analysis with oblique rotation (oblimin) was per-
formed in SPSS® version 25.
Animal experiments. Animal experiments were performed with the approval of
the Regierung der Oberpfalz in accordance with the German Animal Welfare Act,
approval 54-2332.1-23/10 and approval 54-2532.1-10/12. Mouse Mregs were
generated from 8- to 12-week-old C3H mice and administered to 8- to 12-week-old
BALB/c recipients according to previously published methods12. NSG (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) mice were bred in-house and were used at 8–12 weeks of
age. For administration to mice, human and mouse Mregs were resuspended in
1 ml DPBS containing 62 U heparin and then delivered by slow injection into the
tail vein. Animals were randomly allocated to treatment or control groups by a
blinded operator.
Study approval. Mreg_UKR products were administered to consenting kidney
transplant recipients who were participating in the ONEmreg12 trial (clinicaltrials.
gov: NCT02085629) authorised by the Paul Ehrlich Institute (EudraCT-Nr. 2013-
000999-15) and the Ethics Committee of University Hospital Regensburg (14-111-
0016). ONEmreg12 is a non-commercial, investigator-initiated, monocentre, single-
arm, phase-II trial operating within the framework of ONE Study cell therapy trials
(www.onestudy.org). Collection of mononuclear cell apheresates by the Depart-
ment of Transfusion Medicine at University Hospital Regensburg was authorised
by the Regierung der Oberbayern under license DE_BY_04_MIA_2013_0177/53.2-
ZAB-2677.1_204. Production of Mreg_UKR by a contract manufacturing organi-
sation was authorised by the Regierung der Oberbayern under license
DE_BY_04_MIA_2013_0187/53.2-2677.1_A_220-0. This article includes results
from three patients treated according to a modiﬁcation of the TAIC-II Study
protocol (ClinicalTrials.gov: NCT00223067), including two patients whose cases
were previously reported elsewhere.
Fig. 10 Elevated frequency of TIGIT+ TCRVβ13.1+ FoxP3+ Tregs in the peripheral blood of an Mreg-treated kidney transplant recipient at ~7 years after
surgery. The 1-year outcome of an Mreg-treated kidney transplant recipient, who is known as patient CA, has been previously reported. At ~7 years post
transplant, patient CA had stable graft function and was receiving tacrolimus monotherapy as his only maintenance immunosuppression. a At intervals
during the ﬁrst months of follow-up, peripheral blood samples were taken from patient CA for PCR-based TCR spectratyping. These analyses revealed an
oligoclonal expansion of TCRVβ13.1+ T cells that occurred after Mreg administration and persisted throughout the ﬁrst 6 months. b–q At ~7 years post
transplant, peripheral blood samples from patient CA were analysed by ﬂow cytometry for the presence of TCRVβ13.1+ T cells. Compared to 15 healthy
donors without transplants, patient CA was not exceptional with respect to b CD4+ T-cell frequency, c CD4+/CD8+ T-cell ratio or d overall frequency of
FoxP3+ Treg. e Patient CA exhibited only a marginally higher frequency of peripheral blood TIGIT+ CD4+ T cells compared to the reference population.
f Patient CA exhibited a higher frequency of TCRVβ13.1+ T cells in peripheral blood than controls. g Patient CA had a higher proportion of Tregs within
TCRVβ13.1+ CD4+ T cells compared to his overall CD4+ T-cell pool. h By contrast, Tregs were not enriched amongst TCRVβ13.1− CD4+ T cells. i Patient
CA showed a higher ratio of TCRVβ13.1+ Treg to TCRVβ13.1− Treg than healthy controls. j As a proportion of all CD4+ T cells, TCRVβ13.1+ Treg frequency
was higher in patient CA than healthy controls. k Notably, patient CA also exhibited a higher proportion of TCRVβ13.1+ TIGIT+ Treg within the CD4+ T-cell
compartment compared to the reference group. l Consistent with TCR spectratyping results from the ﬁrst 6 months, patient CA exhibited no enrichment of
TCRVβ12+ T cells.m–q Differences between patient CA and healthy controls observed in TCRVβ13.1+ CD4+ T cells were not reﬂected in TCRVβ12+ T cells
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Data availability. The gene expression data presented in this article have been
submitted to the National Center for Biotechnology Information/Gene Expression
Omnibus as data set GSE49369. All other relevant data are available from the
authors without restriction.
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